	US RE50,319 E1
	Compounds and methods for treating cancer
Alan D'Andrea, Winchester, MA (US); Raphael Ceccaldi, Paris (FR); and Jia Zhou, Natick, MA (US)
Assigned to Dana-Farber Cancer Institute, Inc., Boston, MA (US)
Appl. No. 17/984,910
Filed by Dana-Farber Cancer Institute, Inc., Boston, MA (US)
PCT Filed Oct. 16, 2018, PCT No. PCT/US2018/056080 § 371(c)(1), (2) Date Mar. 2, 2020, PCT Pub. No. WO2019/079297, PCT Pub. Date Apr. 25, 2019.
Application 17/984,910 is a reissue of application No. 16/643,689, filed on Oct. 16, 2018, granted, now 11,224,608, issued on Jan. 18, 2022.
Claims priority of provisional application 62/572,977, filed on Oct. 16, 2017.
Int. Cl. A61K 31/7048 (2006.01); A61K 31/357 (2006.01); A61K 31/704 (2006.01); A61K 31/706 (2006.01); A61K 33/243 (2019.01); A61K 45/06 (2006.01); A61P 35/00 (2006.01); C07H 15/20 (2006.01); C07H 17/02 (2006.01); C07H 17/07 (2006.01); C07H 17/075 (2006.01)

CPC A61K 31/7048 (2013.01) [A61K 31/357 (2013.01); A61K 31/704 (2013.01); A61K 31/706 (2013.01); A61K 33/243 (2019.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01); C07H 15/20 (2013.01); C07H 17/02 (2013.01); C07H 17/07 (2013.01); C07H 17/075 (2013.01)]

70 Claims

32. ~~The method of claim 1, wherein the compound of Formula (I) is~~ [ A method of treating a homologous recombination (HR)-deficient cancer, the method comprising administering to a subject in need thereof a therapeutically effective amount of a compound ] selected from the group consisting of:

or a pharmaceutically acceptable salt thereof.